Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers
Hirofumi Yasue(Saiseikai Kumamoto Hospital), Yoshihiko Saito(Nara Medical University), Hisao Ogawa(Jikei University School of Medicine), Minoru Horie(Shiga University of Medical Science), Shiroh Uemura(Nara Medical University), Shuichi Ohshima(Kumamoto Chuo Hospital), Masafumi Nakayama(Kumamoto University), Youichi Hokamura(Kumamoto City Hospital), Yuji Mizuno(Saiseikai Kumamoto Hospital), Seiji Hokimoto(Omuta hospital), Hitoshi Nakagawa(Saiseikai Kumamoto Hospital), Teruhiko Itoh(Saiseikai Kumamoto Hospital), Kiyotaka Kugiyama(University of Yamanashi Hospital), Masaki Harada(Kyoto University), Michihiro Yoshimura(Jikei University School of Medicine), Takasi Honda(Saiseikai Kumamoto Hospital), Shinji Tayama(Saiseikai Kumamoto Hospital), Eisaku Harada(Saiseikai Kumamoto Hospital)
Cited by 177
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449